Regulatory updates (digest-only, lower relevance)
- (57) [regulations.gov] Importer of Controlled-Bright Green(2024-20083)DEA1426
- (57) [regulations.gov] Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429
- (57) [regulations.gov] Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425
- (57) [regulations.gov] Importer Controlled-VA Cooperative (2024-11795) DEA1374
- (57) [regulations.gov] Importer Controlled- Quagen Pharma (2024-11892) DEA1381
- (47) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I
- (45) [regulations.gov] Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I
- (38) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I
- (38) [regulations.gov] Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
- (38) [regulations.gov] Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I
- (35) [regulations.gov] Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I
- (35) [regulations.gov] Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.
- (35) [regulations.gov] Schedules of Controlled Substances: Placement of Metonitazene in Schedule I
- (32) [regulations.gov] Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)
- (5) [regulations.gov] Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)
- (5) [regulations.gov] Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-P)
- (2) [regulations.gov] Definition of Engaged in the Business as a Dealer in Firearms
Digest-Level Clinical Commentary
Clinical Reflection
These regulatory notices suggest ongoing DEA scrutiny of cannabis-adjacent import operations and controlled substance scheduling, which signals that practitioners like myself should remain vigilant about the distinction between federally compliant cannabis products and emerging synthetic cannabinoids that may face accelerated scheduling. The focus on importers and novel compounds indicates the regulatory landscape continues to tighten around unvetted cannabinoid products, reinforcing my practice’s commitment to recommending only well-characterized, state-legal cannabis or pharmaceutically-derived cannabinoids with established safety profiles. While these particular notices don’t directly impact established cannabis medicine, they underscore the broader trend of federal enforcement against the cannabis supply chain’s peripheral actors, which ultimately affects patient access and product reliability.
Clinical Perspective
These regulatory updates reflect ongoing DEA efforts to manage the evolving landscape of controlled substance importation and scheduling. The items indicate continued regulatory activity around synthetic compounds and controlled precursors, which may have implications for pharmaceutical supply chains and clinical access to certain medications. Clinicians should remain aware of scheduling changes and import restrictions that could affect availability of medications used in clinical practice.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: